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Abstract. In May 2005, visceral leishmaniasis (VL) was recognized for the first time in Libo Kemkem, Ethiopia. In
October 2005, a rapid assessment was conducted using data from 492 patients with VL treated in the district health
center and a household survey of 584 residents of four villages. One subdistrict accounted for 71% of early cases, but
the incidence and number of affected subdistricts increased progressively throughout 2004–2005. In household-based
data, we identified 9 treated VL cases, 12 current untreated cases, and 19 deaths attributable to VL (cumulative
incidence, 7%). Thirty percent of participants were leishmanin skin test positive (men, 34%; women, 26%; P  0.06).
VL was more common in men than women (9.7% versus 4.5%, P < 0.05), possibly reflecting male outdoor sleeping
habits. Molecular typing in splenic aspirates showed L. infantum (six) and L. donovani (one). Local transmission resulted
from multiple introductions, is now well established, and will be difficult to eradicate.
INTRODUCTION
In the Horn of Africa, visceral leishmaniasis (VL, kala-
azar) has a focal distribution in two distinct ecologic settings:
the semi-arid regions in the north where Phlebotomus orien-
talis breeds in cracks in the black cotton clay soil and the
savanna and forest areas in the south where the vectors P.
martini and P. celiae are found in association with Macroter-
mes termite mounds.
1,2 In Ethiopia, long-recognized VL-
endemic foci are situated in Metema and Humera along the
border with Sudan in the northwest, reflecting the first eco-
logic pattern, and in the regions of Lake Abaya, Omo River,
and the Aba Roba plains in the south, following the second,
with an estimated country-wide incidence of 2,000 cases/yr
(Figure 1).
3,4 In the northwest Ethiopian foci close to the
Sudan border, 20–30% of patients of VL are also infected
with HIV, the highest co-infection rate in the world.
5 Anthro-
ponotic transmission seems to predominate in the Horn of
Africa, but leishmanial infection has been detected in wild
animals and domestic dogs in Sudan.
6,7 In Ethiopia, the bal-
ance between anthroponotic and zoonotic VL transmission is
unknown. In western Ethiopia, sporadic VL cases are often
attributed to the in-migration of patients infected in eastern
Sudan and Sudanese border localities.
8 While epidemics of
leishmaniasis have not previously been reported in Ethiopia,
East Africa, as a whole has seen an increasing burden of VL
over the last two decades.
9,10
Before 2005, kala-azar cases had never been recognized in
Libo Kemkem wereda (district). In 2004, the Amhara Re-
gional Health Bureau reported a 5-fold increase in crude mor-
tality rates in Libo, attributed initially to an outbreak of drug-
resistant malaria; coartem was provided without effect. In
May 2005, after ∼200 reported deaths, Médecins sans Fron-
tières-Greece (MSF-G) identified the outbreak as kala-azar
(MSF-Greece, unpublished data). From May to June 2005,
MSF-G diagnosed 201 new VL cases with seven additional
deaths and reported that the outbreak had spread to eight
kebeles (subdistricts) with an estimated 50,000 inhabitants at
risk. In October 2005, a rapid outbreak assessment was con-
ducted by local and national health authorities with technical
support from the World Health Organization to define the
extent of the outbreak and describe basic epidemiologic fea-
tures.
MATERIALS AND METHODS
Location. Libo Kemkem wereda is located in the Amhara
Region of northwestern Ethiopia at an altitude of 2,000 m
above sea level. The district is made up of 30 kebeles with an
estimated population of 196,813 in 2004 (Figure 2). Addis
Zemen (the district capital, population 19,755) is located be-
tween Bahir Dar and Gondar on the major road connecting
Addis Ababa to the Red Sea, crossing known foci of intense
VL transmission in Metema, Ethiopia, and Gedaref, Sudan
(dotted line in Figure 1). The district has one health center
and 10 health posts.
Data sources and case definitions. The outbreak study was
conducted from October 8–22, 2005. Two main data sources
were used: 1) records of patients with VL diagnosed and
treated in the MSF-G/Addis Zemen Health Center (AZHC),
the only facility in the district with VL diagnostic capability
and antileishmanial drugs, and 2) a household survey carried
out in four villages.
Kala-azar patients at AZHC were diagnosed predomi-
nantly based on clinical assessment and a positive direct ag-
glutination test (DAT). We calculated dates of symptom on-
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275set retrospectively, based on dates of diagnosis and reported
months of illness in the clinical record. The DAT was per-
formed using standard methods and antigen from ITG-
Belgium; the recommended screening cut-off was used, con-
sidering titers  1:3,200 to be positive.
11 During the field
study, patients suspected of having kala-azar were tested us-
ing two recombinant K39 antigen-based immunochromato-
graphic strip tests, the KalazarDetect (batch FC1098; InBios,
Seattle, WA) and IT-Leish test (Diamed AG, Cressier sur
Morat, Switzerland), in addition to the DAT. They were also
tested using a rapid test for Plasmodium falciparum malaria
(Paracheck Pf; Orchid Biomedical Systems, Goa, India).
12,13
All rapid tests were performed following the manufacturers’
instructions.
MSF-G patient record data were delinked from personal
identifiers at the time of data entry. Written informed consent
was obtained from patients with VL who underwent splenic
aspirate for parasitologic diagnosis.
Household survey. No population estimates were available
for entities smaller than kebeles; representative sampling
was therefore not possible. To validate the facility-based data
and confirm the epidemic nature of the disease in Libo
Kemkem, we therefore performed a rapid epidemiologic
assessment that included three villages reported to be highly
affected and one village close to the highly affected villages
but with only a few reported cases. The three highly affected
villages were chosen from Bura kebele (population 6,321),
the apparent center of the epidemic; all had multiple recent
cases of kala-azar reported in AZHC data. The less affected
village was selected from Shina (population 4,480), a few ki-
lometers away from Bura, to ascertain the presence or ab-
sence of a background of existing endemic VL transmission.
The team attempted to enumerate and include all households
in each survey village, but because of logistic constraints and
the uncertainty of village limits, some houses were not in-
cluded.
The survey was conducted by Ethiopian nurses specifically
trained in the use of the survey questionnaires and application
and reading of the leishmanin skin test (LST). Oral informed
consent was obtained from each person included in the house-
hold survey. Structured questionnaires were used to enumer-
ate all members residing in the household for  6 months in
the last 2 years. For each individual, age and sex were re-
corded, and the nurses used an abbreviated medical history to
ascertain probable and definite kala-azar cases with symptom
onset since New Year’s Day 1996 by the Ethiopian calendar,
equivalent to September 11, 2003. Patients with kala-azar
were characterized as confirmed past cases (diagnosed at
AZHC and treated with 28 days of intramuscular sodium
stibogluconate at a dose of 20 mg/kg/day; SSG; Albert David
Ltd., Kolksta, India); confirmed current cases (> 1 month of
fever and malaria ruled out by rapid test, plus at least one
of the following: weight loss, abdominal pain or swelling,
and positive DAT serology during the field survey), or prob-
able kala-azar deaths (death after an illness with > 1 month
of fever plus weight loss, abdominal pain or swelling, and no
FIGURE 1. The major foci of kala-azar in the Horn of Africa, indicating the location of Libo Kemkem district.
ALVAR AND OTHERS 276other known cause of death). Because kala-azar is close
to 100% lethal without treatment, we sought to identify
people who might have died of kala-azar, especially before
the availability of diagnostic and treatment capability in
AZHC. Family members were asked to describe all deaths
that occurred during the study period. Interviewers probed
for the characteristics outlined above, other descriptors that
would indicate probable cause of death, and what the family
had been informed was the cause of death. Only deaths meet-
ing the above case definition, and without another reported
or probable cause, were included as probable kala-azar
deaths. Leishmanin skin testing was conducted for all con-
senting participants older than 1 year of age, using L. major
antigen (leishmanin batch 122; Pasteur Institute, Tehran,
Iran).
Parasitologic analysis. Splenic aspirates were obtained
from seven patients clinically suspected to have kala-azar.
These samples were examined microscopically and inoculated
in NNN medium. To identify the Leishmania species in the
samples collected, three different approaches were used. Two
techniques identified all Old World Leishmania species and
L. donovani to the complex level: 1) sequence analysis of the
LnPCR product (SSUrRNA region)
14 and 2) HaeIII restric-
tion fragment length polymorphism (RFLP) analysis of the
ITS-1 PCR product (ITS-1 region).
15 To differentiate be-
tween L. infantum and L. donovani, a third technique, HaeIII
RFLP analysis of the T2B4 PCR product (repetitive nuclear
DNA sequence), was used.
16
In addition, venous blood specimens were collected from
40 asymptomatic dogs living in the three highly affected sur-
vey villages in Bura. Molecular characterization of the Leish-
mania species infecting dogs was done with the same meth-
odology used for human specimens.
RESULTS
Facility-based data. Records were available for 492 kala-
azar patients diagnosed at AZHC between May 10 and Oc-
tober 18, 2005. Of these, 344 (74%) were men and 121 (26%)
women (data missing for 27). The mean age was 17.4 years
(median, 16 years; range, 0.7–60 years); female patients were
younger than men (mean, 14.5 versus 18.6 years for men; P <
0.001). Of 490 patients with outcome data, 21 (4%) were
known to have died. Patients came from 47 kebeles in 3 were-
das (Libo Kemkem, Fogera, and Mecha), but 87% of patients
came from just 10 kebeles and 42% from Bura kebele (Table
1; Figure 2). Dates of symptom onset could be calculated for
357 patients: the earliest onset date was April 2003 (Figure 3).
Of the 110 cases with symptom onset between April 2003 and
December 2004, 78 (71%) occurred in Bura kebele. The out-
break began to expand beyond Bura by late 2004: among 247
FIGURE 2. Map of Libo Kemkem and Fogera weredas (districts) indicating the kebeles (subdistricts) affected by the visceral leishmaniasis
outbreak.
KALA-AZAR OUTBREAK IN LIBO 277patients with onset in January 2005 or later, 170 (69%) came
from outside Bura kebele. The patients with kala-azar diag-
nosed during the first massive screening effort in May 2005
had been ill for a mean of 6 months, but the mean duration
fell to < 3 months by September 2005 (Table 1). Only three
cases of post-kala-azar dermal leishmaniasis (PKDL) were
diagnosed from April to October 2005.
Community survey. The survey included 592 members of
125 households in the four villages. Among the 584 individu-
als for whom kala-azar status could be determined, 40 (6.8%)
met a case definition for confirmed or probable kala-azar (9
cases diagnosed and treated at AZHC, 12 current untreated
cases, and 19 deaths after an illness consistent with kala-azar).
The epidemiologic curve based on community data (Figure 4)
was consistent with that for facility-based cases (Figure 3).
The cumulative incidence was higher among men (9.7%) than
women (4.5%; P < 0.05). The median age of kala-azar pa-
tients was 15.5 years compared with 17 years for the popula-
tion as a whole (P  0.53). A total of 27 deaths were reported
in the study population; deaths attributed to kala-azar oc-
curred in significantly older individuals (median age, 16 ver-
sus 3 years; P < 0.05), who were more likely to be men (68%
versus 25%, P < 0.05). Seventy-nine percent of deaths attrib-
uted to kala-azar occurred before VL diagnostic testing be-
TABLE 1
Geographic distribution, age, and duration of illness among kala-azar patients diagnosed at Addis Zemen Health Center from May to October
2005
Month of diagnosis
May June July August September October
By location of residence N (%) n n n n n n
Wereda Kebele
Libo Agita 25 (5) 0 2 4 7 8 4
Libo Angot 66 (13) 11 2 6 12 28 7
Libo Birra Abo 12 (3) 2 2 4 1 2 1
Libo Bura 205 (42) 114 24 20 15 10 22
Libo Shina 14 (3) 1 3 2 3 3 2
Libo Tibaga 20 (4) 2 3 5 2 5 3
Libo Yifag 18 (4) 1 7 3 6 0 1
Fogera Dibasifatra 25 (5) 3 3 4 6 4 5
Fogera Rib Gebriel 30 (6) 0 4 2 3 12 9
Fogera Wotemb 11 (2) 0 0 0 3 4 4
Other locations 66 (13) 6 4 12 17 14 13
All locations 492 (100) 140 54 62 75 90 71
Mean months of illness N  357* 6.1 5.6 5.2 4.2 2.9 2.8
Median age in years among
Patients from Bura kebele N  205 15.5 11.5 16.0 19.0 8.5 4.5
Patients from all other kebeles N  266† 18.0 17.0 20.0 17.0 11.5 15.0
* Illness duration before diagnosis; data missing for 135 patients.
† Data missing for 21 patients.
FIGURE 3. Epidemiologic curve for 357 patients with kala-azar diagnosed from May to October 2005 by MSF-Greece at Addis Zemen Health
Center. Date of symptom onset missing for 135 patients.
ALVAR AND OTHERS 278came available at AZHC (Figure 4). Among 39 patients with
definite or probable kala-azar, 16 (76%) of 21 with onset in
2003 or 2004 died compared with 3 (16%) of 19 with onset in
2005 (P < 0.0001).
Leishmanin skin tests (LSTs) were applied and read 48
hours later for 459 participants. The prevalence of posi-
tive LST was higher among men (34%) than women (26%;
P  0.06) and rose significantly with age among men (
2
for trend 28.5, P < 0.00001) but not women (
2 for trend 2.9,
P  0.09; Table 2). There were consistent differences in the
cumulative incidence of kala-azar and the prevalence of posi-
tive LST by village (Table 3); the ratio of positive LST to
clinical kala-azar ranged from 2.5:1 to 4:1. A total of 14 men
were reported to have spent time in Metema, Humera, or
other areas bordering Sudan, but no significant association
was found with risk of kala-azar (P  0.63). Men who re-
ported travel to these areas were more likely to be LST posi-
tive (8/11; 73%) than other men 18 years of age (43/89;
48%), but this difference did not reach statistical significance
(P  0.13).
Parasitology. Leishmania DNA was detected in all seven
splenic aspirates by all three PCR techniques used.
In addition, NNN culture was positive in six and micros-
copy in three of seven specimens. Sequence of LnPCR prod-
ucts and RFLP analysis of the ITS-1 PCR products confirmed
that all belonged to the L. donovani complex, whereas RFLP
analysis of the T2B4 PCR product indicated that six isolates
were L. infantum and one was L. donovani.
LnPCR amplified Leishmania DNA in the blood of 2 of the
40 dogs studied. Both samples belonged to the L. donovani
complex, but further analysis of the ITS-1 and T2B4 regions
was precluded by the scarcity of Leishmania DNA.
DISCUSSION
This rapid epidemiologic assessment confirmed a major
new outbreak of VL in Libo Kemkem wereda, a highland
district of Ethiopia where the disease had never before been
reported. The epidemiologic picture, with a few cases over a
1-year period followed by an explosive increase, is consistent
with the rapid emergence of the disease in a population with
little pre-existing immunity. The data indicate that the out-
break began in Bura kebele as one or more foci of limited
transmission in early 2003, followed by a marked increase in
cases and deaths in the last several months of 2004, when it
TABLE 2
Prevalence of positive leishmanin skin test by sex and age, household
survey in Libo Kekmen wereda, Ethiopia, October 2005
Age group
(years)
Leishmanin skin test positive [N (%)]/total tested
Men
[n/N (%)]
Women
[n/N (%)]
Both sexes
[n/N (%)]
< 5 2/34 (6) 2/20 (10) 4/54 (7)
5–9 8/45 (18) 6/34 (18) 14/79 (18)
10–14 13/45 (29) 10/33 (30) 23/78 (30)
15–19 14/27 (52) 10/32 (31) 24/59 (41)
20–39 26/57 (46) 13/54 (24) 39/111 (35)
 40 17/31 (55) 15/47 (32) 32/78 (41)
Total 80/239 (34) 56/220 (26) 136/459 (30)
TABLE 3
Cumulative kala-azar incidence from September 11, 2003 through
October 22, 2005, and prevalence of positive leishmanin skin test
by village, household survey in Libo Kekmen wereda, Ethiopia
Kebele Village
Cumulative kala-azar incidence
[n/N (%)]
Positive leishmanin skin test
[n/N (%)]
Bura 1 18/132 (14) 50/100 (50)
Bura 2 12/133 (9) 48/107 (45)
Bura 3 8/163 (5) 32/122 (26)
Shina 4 2/156 (1) 6/130 (5)
Total 40/584 (7) 136/459 (30)
FIGURE 4. Kala-azar cases and probable kala-azar deaths by month of symptom onset; household survey data are from four villages in Libo,
October 2005. Month of symptom onset could not be determined for one kala-azar case.
KALA-AZAR OUTBREAK IN LIBO 279was first brought to the attention of health authorities. Our
community data suggest that the reported cases may repre-
sent less than one half the true total, with many patients dying
before treatment was available. An even greater increase in
cases occurred in 2005, and the outbreak showed no sign of
abating. As of July 2006, a total of 1,841 patients with kala-
azar had been treated by MSF-G in Addis Zemen (MSF-
Greece, unpublished data, 2006).
The mean illness duration before diagnosis fell from 6
months in May 2005 to 3 months in October 2005, reflecting
increased awareness in affected communities and improved
diagnostic availability at the AZHC. Based on the community
data, case-fatality rates seem to have fallen sharply as
well, confirming that the current clinical approach is function-
ing well. With adequate treatment, kala-azar case-fatality
rates are < 5%, and patients generally respond quickly to
antimonials in the Horn of Africa.
9 However, this outbreak
has placed the local health care system under substan-
tial strain. Moreover, our community data, in which we as-
certained more currently ill, undiagnosed VL cases than
treated cases, suggest that the patients reaching AZHC rep-
resent only a fraction of the total who would be identified by
active case finding. Support and commitment are urgently
needed for ongoing diagnostic and treatment services and to
increase clinical capacity to allow active case detection in
communities.
Kala-azar has been known to occur in migrant workers
returning from the cotton, sesame and sorghum fields of Hu-
mera and Metema on the Sudan border since the 1970s.
4,17,18
Migrant workers sleep in rough shelters or the open air under
acacia trees, placing them at high risk for exposure to bites of
the leishmanial vector P. orientalis.
17,18 Leishmanin surveys in
the border area suggest intense transmission in the migrant
population.
17 The only previous report of kala-azar in the
highlands east of Lake Tana described six cases in Belessa
wereda, another highland area around 130 km north from
Libo, with very similar ecology. In Belessa, P. orientalis was
implicated as the vector, and at least two patients were chil-
dren who had never traveled outside of the district.
8 No fur-
ther transmission in the area was reported.
In both the Belessa cluster
8 and the Libo outbreak, inves-
tigators hypothesized that agricultural migrant workers re-
turning from the Sudanese border area introduced VL into
highland communities. Among adult men surveyed in Libo in
2005, 4% had worked in Metema and 8% in Humera in the
previous 3 years. Those who worked in the border zone were
more likely to be skin test positive, suggesting that they had
leishmanial exposure there, but they had no higher incidence
of kala-azar than their neighbors who had not traveled. The
outbreak study thus could not prove the hypothesis that leish-
maniasis was introduced into Libo by returning seasonal
workers but supported the possibility. Nevertheless, in con-
trast to the isolated report from Belessa, VL transmission is
now well established in Libo Kemkem and spreading into
neighboring districts; the area seems destined to become a
VL-endemic focus. Spurred by recurrent famine and
droughts, the Ethiopian government established a program to
resettle thousands of people from drought-affected areas that
have no leishmanial transmission to the more fertile but VL-
endemic areas bordering Sudan. The Libo outbreak raises the
possibility that both resettled people and highland communi-
ties to which they return will be at high risk for lethal epi-
demics of VL.
The limitations of this rapid assessment leave several un-
answered questions. The small number of leishmanial isolates
from humans and dogs does not allow us to draw a definitive
conclusion regarding the relative contributions of zoonotic
and anthroponotic transmission. Moreover, the responsible
sand fly species has not yet been proven. In the facility-based
data, some records lacked data on specific variables such as
illness duration or sex. In the community-based data, we as-
certained probable deaths from kala-azar based on the report
of family members, and some of the deaths may have had
some other unidentified cause. Nevertheless, the data from
the two sources taken together present a consistent picture of
an explosive focal outbreak with high mortality followed by
sustained transmission. Both disease and infection rates were
significantly higher in men than women. This finding may
reflect the male tendency to sleep outdoors to guard their
cattle (Figure 5) and suggests that transmission may occur
predominantly outside the house, hypotheses that should be
tested in a more detailed study of behavioral and other risk
factors.
Despite the relatively small number of isolates, both L.
donovani and L. infantum were identified in Libo Kemkem,
as previously reported in Kenya,
19 Sudan,
20 and Ethiopia (A.
Hailu, personal communication, 2005). The detection of two
Leishmania species and multiple genotypes (data not shown)
indicates that multiple parasite introductions must have oc-
curred into the outbreak area. L. infantum was more fre-
quently identified than L. donovani, consistent with the low
reported PKDL prevalence and raising the potential role of
dogs as an epidemiologically important reservoir host. In-
deed, the presence of leishmanial infection in the dog popu-
lation was confirmed by the amplification of Leishmania
DNA from two dogs. Molecular analysis of the amplified
products indicated infection by the L. donovani complex, but
species-level identification was impossible because of the
scarcity of DNA in the samples. Although suggestive, these
preliminary results are not sufficient to clarify the role of the
dog in this outbreak. Further study may clarify the epidemio-
logic significance of our findings and help resolve the ongoing
controversy surrounding the taxonomy of the L. donovani
complex in the region.
21
FIGURE 5. Bed adjacent to shelter in Bura. Sleeping outside may
be a risk factor for infection because of higher exposure to sand fly
bites.
ALVAR AND OTHERS 280However, the most important unanswered question is why
transmission in Libo Kemkem and neighboring districts
reached epidemic levels in 2004 and has continued to increase
since then, rather than burning out, as seems to have hap-
pened in the past.
8 In the Horn of Africa, VL epidemics fre-
quently occur in the wake of war, population displacements,
famine, and drought.
10,22 However, the population of Libo
was stable through 2005, and no dramatic changes in agricul-
tural production or cattle populations were reported. Based
on the limited available data, we hypothesize that VL trans-
mission in Libo may have been sustained focally and at low
levels for many years, occasionally coming to light in studies
such as the 1973 study.
8
In summary, the VL outbreak in Libo Kemkem and neigh-
boring weredas seems to be fueled by a well-established trans-
mission cycle caused by two different Leishmania visceraliz-
ing species. The geographic spread and rapid, sustained pro-
gression over the last 2 years suggest that VL transmission
will not be easy to eradicate. The most urgent need is to
strengthen the capacity of local health facilities to ensure
availability of early, accurate diagnostic testing followed by
appropriate antileishmanial treatment. Until the detailed
transmission cycle, sand fly species and risk factors are fully
described, the use of insecticide-treated bed nets may help to
stem the growth of this epidemic. Further studies in humans
and dogs, as well as entomologic studies during the appropri-
ate season, will be essential to develop a comprehensive long-
term control strategy.
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